However, it should be noted that residual T cells after 5 days of LDC526 therapy were primarily CD4+ T cells, which were shown to be indispensable for CLL proliferation in NSG spleens [29]. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.